13-02-2023, 19:03

ONL Therapeutics to Present at the XXVth Biennial Meeting

Oral presentation will review the scientific rationale for Fas receptor inhibition, a unique mechanism-of-action, in
Globe Newswire13-02-2023, 19:03
2-02-2023, 19:05

ONL Therapeutics to Present at 2023 BIO CEO & Investor

ANN ARBOR, Mich., Feb. 02, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company
Globe Newswire2-02-2023, 19:05